What is the price-to-earnings ratio of Formycon?
The price-earnings ratio of Formycon is currently -199.3.
Formycon P/E 2024
Formycon P/E
-199.3
Formycon Dividend yield
Ticker
FYB.DE
ISIN
DE000A1EWVY8
WKN
A1EWVY
As of May 21, 2024, Formycon's P/E ratio was -199.3, a -1,419.87% change from the 15.1 P/E ratio recorded in the previous year.
The Formycon P/E history
Formycon Aktienanalyse
What does Formycon do?
Formycon AG is a German biotechnology company that was founded in 2010 in Martinsried near Munich. The company's history mainly began with the development of an innovative technology concept that allows for the cost-effective and efficient production of biosimilars. The market entry started in 2017 with the launch of the first proprietary biosimilar on the European market. The core business of Formycon AG is the production and distribution of biosimilars. These are biological drugs that have a similar structure and efficacy to already approved original drugs. The development of biosimilars is complex due to the elaborate manufacturing process and high-quality assurance requirements, requiring innovative ideas and technologies. Formycon AG has developed its innovative platform technology, FORMYCON® NEXT LEVEL, which allows the company to cost-effectively produce large quantities of proteins used in cancer therapy, immunotherapy, and the treatment of autoimmune diseases. Formycon AG is divided into various divisions, including research and development, production, and distribution. In research and development, new biosimilars and other innovative technologies are developed to further improve production processes. Production takes place in a dedicated biotechnological production facility in Roth near Nuremberg, where up to eight different medications can be produced simultaneously. In the distribution sector, Formycon AG collaborates with partners who market and distribute the biosimilars in different countries. The company operates internationally, with a presence in Europe, the USA, and Asia. The biosimilars produced by Formycon AG are a cost-effective alternative to the existing original drugs. The products are used in the fields of oncology, immunology, and ophthalmology, offering patients a chance to receive effective therapy at an affordable price. Successful marketing and high demand contribute to positive company development. In 2020, Formycon AG generated a revenue of 25 million euros and currently employs approximately 150 staff members. An example of a biosimilar produced by Formycon AG is the drug FYB202, which is used for the treatment of breast, ovarian, and salivary gland cancer. It is a replica of the breast cancer medication Herceptin®, developed and distributed by the Swiss company Roche. The FYB202 biosimilar has shown in clinical studies that it is similarly effective as Herceptin® but represents a more cost-effective alternative for patients. Overall, Formycon AG pursues a sustainable business model with a focus on the development of cost-effective biosimilars. The innovative technology and focus on cost-effective production enable the company to achieve a strong market presence and offer an effective alternative to conventional drugs. Formycon ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Formycon's P/E Ratio
The Price to Earnings (P/E) Ratio of Formycon is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Formycon's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Formycon is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Formycon’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Formycon Stock
How has the price-earnings ratio of Formycon changed compared to last year?
The price-to-earnings ratio of Formycon has increased by -1,419.87% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Formycon high compared to other companies?
Yes, the price-to-earnings ratio of Formycon is high compared to other companies.
How does an increase in the price-earnings ratio of Formycon affect the company?
An increase in the price-earnings ratio of Formycon would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Formycon affect the company?
A decrease in the price-earnings ratio of Formycon would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Formycon?
Some factors that influence the price-earnings ratio of Formycon are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Formycon pay?
Over the past 12 months, Formycon paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Formycon is expected to pay a dividend of 0 EUR.
What is the dividend yield of Formycon?
The current dividend yield of Formycon is .
When does Formycon pay dividends?
Formycon pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Formycon?
Formycon paid dividends every year for the past 0 years.
What is the dividend of Formycon?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Formycon located?
Formycon is assigned to the 'Health' sector.
Wann musste ich die Aktien von Formycon kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Formycon from 5/21/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 5/21/2024.
When did Formycon pay the last dividend?
The last dividend was paid out on 5/21/2024.
What was the dividend of Formycon in the year 2023?
In the year 2023, Formycon distributed 0 EUR as dividends.
In which currency does Formycon pay out the dividend?
The dividends of Formycon are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Formycon stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Formycon
Our stock analysis for Formycon Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Formycon Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
